TNFRSF11A and breast carcinoma: The receptor activator of nuclear factor κB, known as RANK, member of tumor necrosis factor receptor (TNFR) superfamily, and its ligand (RANKL) have emerged as potential therapeutic targets in breast cancer (BC) and other solid tumors [1–3].